This free sheet contains 100 accelerators and incubators you can apply to today, along with information about the industries they generally invest in.
This free sheet contains all the information about the top 100 unicorns, including their valuation, HQ's location, founded year, name of founders, funding amount and number of employees.
This free Notion document contains the best 100+ resources you need for building a successful startup, divided in 4 categories: Fundraising, People, Product, and Growth.
The therapeutics sector is seeing major investment across many areas of health. Companies are tackling everything from cancer treatment to mental healthcare access.
For example, Avenzo Therapeutics has raised over $841 million for oncology since 2022. The field also includes companies like Midi Health, which focuses on virtual care for women.
Below is our list of 100 Therapeutics startups worth keeping an eye on.
Everything you need to raise funding for your startup, including 3,500+ investors, 7 tools, 18 templates and 3 learning resources.
Buy It For $97 $297 →Information about the industries, countries, and cities they generally invest in.
Get the Sheet for $50Information about their valuation, HQ's location, founded year, name of founders, funding amount and number of employees.
Get the Sheet for $50List of startup investors in the BioTech, Health, and Medicine industries, along with their Twitter, LinkedIn, and email addresses.
Get the Sheet for $50List of 250 startup investors in the AI and Machine Learning industries, along with their Twitter, LinkedIn, and email addresses.
Get the Sheet for $50List of 250 startup investors in the FinTech and Finance industries, along with their Twitter, LinkedIn, and email addresses.
Get the Sheet for $50Odyssey Therapeutics creates precision medicines to treat patients with cancer and inflammatory diseases. Their discovery platform combines machine learning with deep expertise in biology and chemistry to develop novel immunomodulators and oncology drugs.
Midi Health built a virtual care platform to support women through menopause and other midlife health transitions. The service connects patients with trained clinicians who provide personalized treatment for hormonal changes and related conditions.
Enveda Biosciences develops novel medications by exploring the chemical compounds found in plants. Their drug discovery platform uses machine learning to identify promising molecules for new therapeutics.
Headway builds a mental healthcare system that makes it easier for patients to find a therapist who accepts their insurance. Their platform also helps providers by enabling them to accept insurance and scale their private practices.
Avenzo Therapeutics develops targeted oncology therapies designed to treat various forms of cancer. The company focuses on advancing its clinical pipeline to provide new options for patients with unmet medical needs.
Character Biosciences built a platform that merges genomics, clinical data, and AI to find new ways to treat complex diseases. Their work currently focuses on Age-related Macular Degeneration (AMD), aiming to develop novel diagnostics and therapeutics for patients.
CHARM Therapeutics applies 3D deep learning to discover and develop novel small molecule medicines against difficult-to-drug targets. Their proprietary platform, DragonFold, powers a lead program in oncology that targets a key protein interaction driving acute leukemias.
SetPoint Medical develops a bioelectronic medicine platform to treat chronic autoimmune diseases. Their proprietary device stimulates the vagus nerve, offering a new therapeutic approach for conditions like rheumatoid arthritis as an alternative to drug therapy.
Grow Therapy created a mental health marketplace that connects patients with therapists who match their needs and insurance. The platform empowers therapists by handling administrative tasks like booking and billing, allowing them to launch and grow their own private practices.
Massive Bio built an AI-powered platform to connect cancer patients with personalized clinical trial options. Their service helps patients access advanced treatments while allowing pharmaceutical companies to more easily find participants for oncology research.
Those top 10 companies are just a small slice of what’s happening in the field. A huge number of new startups are focused on biotech and AI to develop new treatments.
In total, the companies on our list have raised over $15 billion, showing a big vote of confidence from investors. Here’s a look at the other startups that are pushing the industry forward.
| Startup | Main Industry | Year Founded | Amount Raised | Last Funding Round |
|---|---|---|---|---|
| Biotech | 2013 | $156.3M | Series B | |
| Healthcare | 2015 | $248.5M | Series C | |
| Biotech | 2016 | $181.2M | Venture Round | |
| Healthcare | 2018 | $315M | Series D | |
| AI | 2015 | $493.5M | Venture Round | |
| Biotech | 2019 | $355M | Series C | |
| Biotech | 2018 | $127.3M | Series B | |
| Biotech | 2019 | $258M | Venture Round | |
| Education | 2009 | $414.2M | Private Equity | |
| Biotech | 2017 | $257.2M | Series B | |
| Biotech | 2020 | $180M | Venture Round | |
| Biotech | 2016 | $40M | Series A | |
| Biotech | 2023 | $28.6M | Series A | |
| Healthcare | 2016 | $154.1M | Series C | |
| Biotech | 2021 | $180M | Angel | |
| AI | 2019 | $203M | Series B | |
| Biotech | 2017 | $120M | Convertible Note | |
| Biotech | 2018 | $287M | Series C | |
| AI | 2022 | $42M | Series A | |
| Biotech | 2004 | $22.7M | Grant | |
| Biotech | 2017 | $1.1B | Grant | |
| Biotech | 2012 | $1B | Series C | |
| Healthcare | 2022 | $270M | Series A | |
| Biotech | 2020 | $46M | Series A | |
| Healthcare | 2021 | $75M | Series A | |
| Biotech | 2018 | $346.1M | Series D | |
| Biotech | 2019 | $175.9M | Undisclosed | |
| Biotech | 2020 | $119.8M | Grant | |
| Biotech | 2019 | $34M | Undisclosed | |
| Biotech | 2020 | $59.2M | Series A | |
| Biotech | 2021 | $122M | Series B | |
| AI | 2023 | $65M | Series A | |
| AI | 2019 | $32.3M | Venture Round | |
| Biotech | 2012 | $207.5M | Series D | |
| Healthcare | 2017 | $85.2M | Series C | |
| Biotech | 2010 | $23M | Corporate Round | |
| Manufacturing | 2016 | $79.4M | Series C | |
| Healthcare | 2018 | $90.5M | Venture Round | |
| Biotech | 2020 | $315.2M | Venture Round | |
| Healthcare | 2018 | $32.8M | Grant | |
| Healthcare | 2020 | £73M | Series A | |
| Biotech | 2007 | $85.7M | Corporate Round | |
| Biotech | 2020 | $56.1M | Series A | |
| Biotech | 2022 | $216M | Series A | |
| Biotech | 2025 | $205M | Series A | |
| Biotech | 2020 | $365M | Corporate Round | |
| Biotech | 2021 | $100M | Venture Round | |
| Biotech | 2019 | $321M | Series B | |
| Biotech | 2019 | $30M | Series A | |
| Biotech | 2019 | $237.6M | Series C | |
| Biotech | 2012 | $64.2M | Series A | |
| Biotech | 2019 | $72.5M | Venture Round | |
| AI | 2023 | $1B | Series A | |
| Biotech | 2020 | $47.2M | Series B | |
| Healthcare | 2017 | $114.4M | Series C | |
| AI | 2019 | $99.3M | Series B | |
| AI | 2017 | $123.3M | Venture Round | |
| Biotech | 2020 | $2.3M | Corporate Round | |
| Biotech | 2013 | $115M | Series C | |
| Biotech | 2017 | $5.6M | Debt Financing | |
| Healthcare | 2014 | $216.5M | Venture Round | |
| Biotech | 2001 | $110M | Series C | |
| Biotech | 2020 | $236M | Series B | |
| Biotech | 2018 | $643M | Series C | |
| Healthcare | 2014 | $183M | Series C | |
| Biotech | 2018 | $15.5M | Seed | |
| AI | 2018 | $26.7M | Venture Round | |
| Healthcare | 2017 | $162.5M | Series D | |
| Biotech | 2015 | CHF31.3M | Convertible Note | |
| AI | 2020 | $447M | Series D | |
| Sports | 2021 | $29M | Series A | |
| Biotech | 2024 | $370M | Series A | |
| Biotech | 2018 | $241M | Series C | |
| Biotech | 2011 | $180M | Grant | |
| AI | 2014 | $52.1M | Series B | |
| Biotech | 2015 | $148M | Series B | |
| Biotech | 2021 | $100M | Series A | |
| Biotech | 2024 | $140M | Series A | |
| Biotech | 2021 | $44.8M | Seed | |
| Biotech | 2021 | $340M | Series B | |
| Healthcare | 2010 | $499.5M | Venture Round | |
| Healthcare | 2000 | $252M | Private Equity | |
| Biotech | 2017 | $149.5M | Series D | |
| Biotech | 2018 | $16.1M | Series A | |
| Biotech | 2018 | $128.6M | Series B | |
| Biotech | 2021 | $208M | Series B | |
| Biotech | 2018 | $159M | Series B | |
| Biotech | 2020 | $173M | Series B | |
| Healthcare | 2022 | $55.2M | Series B | |
| AI | 2020 | $27.8M | Seed |
